The Centers for Medicare & Medicaid Services (CMS) finalised a permanent framework for negotiating the prices of high-cost drugs on 5 November 2026. The final rule, CMS-4215-F, sets the ongoing policies for the Medicare Drug Price Negotiation Program, with negotiated prices taking effect from 2029. The rule is effective on 5 December 2026.
What the Final Rule Locks In
For the first three years of the programme, covering prices that take effect in 2026 through 2028, the law directed CMS to run the negotiation programme through guidance and other programme instructions. This final rule puts the policies for 2029 and beyond into regulation, giving drugmakers a clearer and more predictable process. Sections 11001 and 11002 of the Inflation Reduction Act of 2022 set up the programme to negotiate maximum fair prices for certain high-expenditure, single-source drugs and biological products.
By 1 February 2027, CMS will select up to 20 additional negotiation-eligible drugs covered under Part D or payable under Part B, as well as drugs for renegotiation where appropriate, for the fourth cycle of negotiations. CMS Administrator Mehmet Oz said the rule provides additional tools to help CMS negotiate better deals, achieve greater savings for taxpayers and beneficiaries, and improve health outcomes for seniors who rely on the Medicare prescription drug programme.
Fixed Combination Drugs and the Small Biotech Floor
The most contested part of the rule concerns fixed combination drugs. CMS finalised its proposed approach to certain fixed combination drugs that it considers new formulations of existing drugs. The policy is meant to stop a manufacturer from moving patients to a new formulation to get around the maximum fair price that applies to the original drug, by treating the combination as the same drug for negotiation purposes.
The rule also implements the temporary floor for small biotech drugs required by law, which stops CMS from offering or accepting a counteroffer below a specified price floor for certain eligible small biotech drugs for the 2029 and 2030 price years. The Partnership to Fight Chronic Disease said on 5 November that the fixed combination policy could discourage the development of new combination therapies and more convenient ways to take medicines, and urged CMS and Congress to protect incentives for treatments that are more effective and easier to use. Drugmakers are also expected to challenge the rule in court, with the fixed combination provision seen as the likely flashpoint.
What Part D Plans and Pharmacies Must Do
The rule also puts two Part D policies into regulation. Part D plans must include selected drugs with a maximum fair price in effect on their formularies, and the negotiated prices plans pay pharmacies and other dispensing entities are capped at the maximum fair price plus any dispensing fees.
The American Hospital Association, in comments on the proposed rule in August, urged CMS to require drugmakers to provide the maximum fair price at the point of sale rather than through retrospective rebates. The group said a rebate approach would burden hospitals, especially rural, critical access and safety-net facilities, and could pave the way for a similar shift in the 340B programme.
Why This Matters for Healthcare Organizations
For hospitals and clinics, the direct effects of this rule are limited for now, since the negotiated prices it governs do not take effect until 2029. The parts to watch are the ones that reach into day-to-day operations. The formulary and pharmacy payment rules shape what Part D plans pay dispensing entities, and the point-of-sale question the hospital association raised will matter for hospitals that dispense negotiated drugs.
For patients, the programme's results so far are the reference point. The first negotiated prices, for 2026, were set through guidance rather than regulation, and this rule is the step that makes the process permanent. Practices that prescribe high-cost Part D drugs should expect the list of negotiated drugs to grow from the fourth cycle onward, with up to 20 more drugs selected by 1 February 2027.
Analysis: Predictability for Drugmakers, Pressure on Combinations
The rule gives both sides something they asked for and one thing each side dislikes. Drugmakers get a codified process with published timelines, which is what the industry has asked for since the programme began. In return, CMS gets the fixed combination provision, which closes a route around the maximum fair price that manufacturers could otherwise have used.
The open question is whether the fixed combination rule chills the development of combination therapies that patients genuinely benefit from, as the Partnership to Fight Chronic Disease argues, or whether it only blocks combinations designed to dodge a negotiated price. That distinction will be tested in court and in the next negotiation cycle, and it is the part of the rule most likely to change before 2029.
Clinics reviewing how front-desk and patient communication work can be handled can explore MedClinicX's AI patient portal, see how after-hours calls are handled on our AI medical receptionist page, or explore the demos and request a quote. For related coverage, see our earlier article on Medicare Part D premiums projected to rise 50% in 2027.
Sources and References
- Centers for Medicare & Medicaid Services — CMS Final Rule Strengthens Supports Lasting Drug Savings, 5 November 2026: https://www.cms.gov/newsroom/press-releases/cms-final-rule-strengthens-supports-lasting-drug-savings
- Centers for Medicare & Medicaid Services — Medicare Drug Price Negotiation Program and Medicare Prescription Drug Benefit Program Final Rule (CMS-4215-F), 5 November 2026: https://www.cms.gov/newsroom/fact-sheets/medicare-drug-price-negotiation-program-medicare-prescription-drug-benefit-program-final-rule-cms
- Federal Register — Medicare Drug Price Negotiation Program and Medicare Prescription Drug Benefit Program Final Rule (CMS-4215-F), document 2026-22792: https://www.federalregister.gov/d/2026-22792
- Becker's Hospital Review — CMS to make drug price negotiation framework permanent, 5 November 2026: https://www.beckershospitalreview.com/legal-regulatory-issues/cms-to-make-drug-price-negotiation-framework-permanent/
- Bloomberg Law — Trump's Drug Negotiation Rule Kicks Off New Fight for Pharma, 5 November 2026: https://news.bloomberglaw.com/health-law-and-business/trump-finalizes-plan-for-fourth-medicare-drug-price-negotiations
- Partnership to Fight Chronic Disease — CMS Final Rule Threatens Innovation and Future Treatment Options for Patients, 5 November 2026: https://www.fightchronicdisease.org/post/cms-final-rule-threatens-innovation-and-future-treatment-options-for-patients
Reporting based on the sources above, accessed 6 November 2026. The CMS press release and fact sheet were read directly, and the Becker's Hospital Review, Bloomberg Law and Partnership to Fight Chronic Disease reports were read directly and cross-checked against them. MedClinicX did not conduct original reporting or interviews for this article. Corrections: contact us via https://medclinicx.com/contact